ANALISIS EFEKTIVITAS BIAYA TERAPI KOMBINASI OBAT GOLONGAN ACE INHIBITOR-BETA-BLOCKER DAN ANGIOTENSIN RECEPTOR BLOCKER-BETA-BLOCKER PADA PASIEN GAGAL JANTUNG DENGAN HIPERTENSI DI RSAU dr. M. SALAMUN

CITRA RETNA GEMILANG, - (2025) ANALISIS EFEKTIVITAS BIAYA TERAPI KOMBINASI OBAT GOLONGAN ACE INHIBITOR-BETA-BLOCKER DAN ANGIOTENSIN RECEPTOR BLOCKER-BETA-BLOCKER PADA PASIEN GAGAL JANTUNG DENGAN HIPERTENSI DI RSAU dr. M. SALAMUN. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.

	Text S_PSSF_A233004_Title.pdf Download (400kB)
	Text S_PSSF_A233004_Chapter1.pdf Restricted to Repository staff only Download (238kB)
	Text S_PSSF_A233004_Chapter2.pdf Restricted to Repository staff only Download (386kB)
	Text S_PSSF_A233004_Chapter3.pdf Restricted to Repository staff only Download (313kB)
	Text S_PSSF_A233004_Chapter4.pdf Restricted to Repository staff only Download (486kB)
	Text S_PSSF_A233004_Chapter5.pdf Restricted to Repository staff only Download (217kB)
	Text S_PSSF_A233004_Appendix.pdf Restricted to Repository staff only Download (1MB)

Abstract

Gagal jantung dengan hipertensi merupakan salah satu masalah kesehatan utama di Indonesia. Data BPJS Kesehatan tahun 2023 menunjukkan bahwa penyakit jantung memerlukan pembiayaan sebesar Rp17,629 triliun untuk 20,04 juta kasus. Penelitian ini bertujuan untuk mengevaluasi perbedaan efektivitas dan biaya terapi kombinasi ACE Inhibitor-Beta-blocker dibandingkan Angiotensin Receptor Blocker-Beta-blocker pada pasien gagal jantung dengan hipertensi. Penelitian ini menggunakan desain retrospektif dengan pengambilan data dari rekam medis dan rincian biaya medis langsung pasien gagal jantung secara purposive sampling di RSAU dr. M. Salamun selama Januari–Desember 2024. Analisis efektivitas biaya dilakukan menggunakan Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER), dan analisis sensitivitas. Hasil menunjukkan efektivitas penurunan tekanan darah sistolik pada kelompok ACE Inhibitor-Betablocker sebesar 3,10 mmHg dan pada kelompok Angiotensin Receptor BlockerBeta-blocker sebesar 3,40 mmHg. Nilai ACER lebih rendah pada kelompok ACE Inhibitor-Beta-blocker sebesar Rp 1.310.787. Nilai ICER menunjukkan biaya tambahan sebesar Rp 1.563.110 untuk setiap penurunan 1 mmHg tekanan darah sistolik jika menggunakan Angiotensin Receptor Blocker-Beta-blocker. Kesimpulan pada penelitian bahwa terapi kombinasi ACE Inhibitor-Beta-blocker lebih cost-effectiveness, dengan kelompok Angiotensin Receptor Blocker-Betasebagai regimen yang paling mempengaruhi efektivitas biaya. ----- Heart failure with hypertension is a significant public health concern in Indonesia. According to data from the National Health Insurance BPJS Kesehatan in 2023, heart disease accounted for a healthcare expenditure of Rp 17.629 trillion for 20.04 million cases. This study aimed to compare the costeffectiveness of combination therapy using ACE inhibitor–Beta-blocker versus Angiotensin Receptor Blocker-Beta-blocker in heart failure with hypertension patients. The study used retrospective design with medical records and direct medical cost data collected via purposive sampling of treated heart failure patients at RSAU Dr. M. Salamun from January to December 2024. The costeffectiveness was analyzed using the Average Cost Effectiveness Ratio (ACER), Incremental Cost Effectiveness Ratio (ICER), and sensitivity analysis. The results showed that the effectiveness of reducing systolic blood pressure was 3,10 mmHg in the ACE inhibitor–Beta-blocker group and 3,40 mmHg in the Angiotensin Receptor Blocker-Beta-blocker group. The ACER was lower in the ACE inhibitor– Beta-blocker group Rp 1.310.787. The ICER indicated an additional cost of Rp 1.563.110 per 1 mmHg reduction in systolic blood pressure when using the Angiotensin Receptor Blocker-Beta-blocker combination. The conclusion in this study is combination of ACE inhibitor–Beta-blocker theraphy was more costeffectiveness. Sensitivity analysis showed that the Angiotensin Receptor BlockerBeta-blocker regimen had the greatest impact on cost-effectiveness outcomes

Item Type:	Thesis (Skripsi)
Uncontrolled Keywords:	efektivitas biaya, gagal jantung, hipertensi, ace inhibitor, angiotensin receptor blocker. ---- cost-effectiveness, heart failure, hypertension, ace inhibitor, angiotensin receptor blocker
Subjects:	R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
Divisions:	Program Studi S1 Farmasi
Depositing User:	pustakawan - -
Date Deposited:	13 Aug 2025 04:14
Last Modified:	28 Aug 2025 01:58
URI:	http://repository.stfi.ac.id/id/eprint/2698

Actions (login required)

View Item